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Every morning we are born again. What we do today is what matters most. 
Buddha 
 
Believe you can and you’re halfway there. 
Theodore Roosevelt 
  
I can’t change the direction of the wind, but I can adjust my sails to always reach my 
destination.  
Jimmy Dean  
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Abstract 
  
Nanoparticles present great potential in drug delivery applications, yet there are some 
issues regarding their stability. In this context, this study was conducted to define the conditions 
to stabilize polysaccharide (chitosan/dextran sulfate, CS/DS) nanoparticles by a process of 
freeze-drying, assessing the cryoprotectant capacity of two sugars (sucrose and glucose). 
Additionally, it was also intended to find if the solubilisation of chitosan in different acids 
affected nanoparticle preparation and characteristics. 
CS/DS nanoparticles were produced by polyelectrolyte complexation and the 
suspensions adjusted to 1 mg/mL or 2 mg/mL. For the study of stabilisation by freeze-drying, 
three approaches were conducted: i) after production of nanoparticles, 5% or 10% (w/v) of 
glucose or sucrose were included in the suspension before freezing, being nanocarriers 
characterized for size and zeta potential before freeze-drying and immediately after freeze-
drying and reconstitution; ii) nanoparticles were produced, and then stored at 4 ºC (no 
cryoprotectants added); iii) nanoparticles were produced, freeze-dried with cryoprotectants and 
then stored, in a desiccator, at room temperature, being characterized (size and zeta potential) 
every 15 days, after the needed reconstitution. 
Acetic acid and hydrochloric acid (HCl) at 0.1 and 0.01 M were used to solubilise 
chitosan. CS dissolved in HCl 0.1 M did not enable the production of nanoscale particles. When 
the remaining acids were test, nanoparticles had sizes above 500 nm. Furthermore, zeta 
potential presented an unexpected behaviour. Thus, it was concluded that this study needs 
optimisation. 
The storage of nanoparticle suspensions at 4 ºC resulted in instability after 50 days. 
Therefore, a freeze-drying approach was established. In general, the choice of cryoprotectant 
was the most important factor affecting the preservation of nanoparticle physicochemical 
characteristics. Moreover, results indicated that in short- and long-term periods, glucose 
presented a more suitable behaviour despite some variations. 
 
Keywords: chitosan, cryoprotectants, dextran sulfate, drug delivery, freeze-drying, 
glucose, nanoparticles, sucrose, stability   
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Resumo 
 
As nanopartículas apresentam-se como uma interessante estratégia de veiculação de 
fármacos. Contudo, a sua estabilidade é uma limitação desenhado este estudo que pretende 
estabelecer condições de estabilização de nanopartículas polissacarídicas (quitosano/sulfato de 
dextrano, CS/DS) através de um processo de liofilização, avaliando-se a capacidade 
crioprotetora de dois açúcares. Adicionalmente, procurou-se entender a influência de diferentes 
ácidos usados na dissolução do quitosano no tamanho e potencial zeta das nanopartículas 
produzidas. 
Nanopartículas de CS/DS foram preparadas por complexação polieletrolítica e as 
suspensões ajustadas a concentrações de 1 e 2 mg/mL. Para a abordagem da liofilização, foram 
delineados 3 ensaios: i) após a produção das nanopartículas, foi adicionado crioprotetor à 
suspensão antes do congelamento e a sua caracterização foi realizada imediatamente após a 
liofilização; ii) as nanopartículas foram produzidas e armazenadas a 4 ºC, sem qualquer adição 
de crioprotetor e iii) as nanopartículas foram produzidas, liofilizadas com crioprotetor, e 
armazenadas num exsicador, à temperatura ambiente, tendo sido caracterizadas de 15 em 15 
dias. 
O ácido acético e o ácido clorídrico (HCl) a 0.1 M e 0.01 M foram os ácidos usados 
para solubilizar o quitosano. Os veículos derivados do uso de quitosano dissolvido em HCl 0.1 
M encontraram-se fora da escala nanométrica. Por outro lado, nos restantes, os tamanhos 
ficaram acima dos 500 nm. Além disso, o potencial zeta demonstrou uma tendência inesperada, 
pelo que este estudo requer otimização. 
O armazenamento de nanosuspensões a 4 ºC resultou em parâmetros de caracterização 
instáveis, a partir do dia 50. Desta forma, estabeleceu-se um protocolo de liofilização em que, 
no geral, a escolha do crioprotector foi o fator determinante que afeta a preservação das 
características fisico-químicas das nanopartículas. Além disso, os resultados sugerem que a 
glucose possui uma melhor capacidade crioprotetora, a curto e longo prazos, apesar das grandes 
variações que os dados revelaram. 
 
Palavras-chave: crioprotetores, estabilidade, glucose, liofilização, nanopartículas, 
quitosano, sacarose, sulfato de dextrano, veiculação de fármacos  
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Resumo Alargado 
 
A medicina é, hoje em dia, uma área em crescente desenvolvimento tal como as ciências 
farmacêuticas. Da mesma maneira que o conhecimento se adensa sobre determinadas 
patologias e outras novas parecem surgir, a forma como se pode abordar o tratamento e o 
diagnóstico das mesmas evolui até novos patamares. Ainda que a regulação a nível de ensaios 
clínicos e de introdução de novas moléculas no mercado esteja cada vez mais apertada, o facto 
é que estes aspetos permitiram que os investigadores focassem as suas atenções em 
problemáticas mais direcionadas para a melhoria do que já está em utilização. Paralelamente, 
a investigação de novas moléculas está naturalmente em curso, mas requer um investimento 
cada vez maior que poderá nunca chegar a ter um retorno. É neste preciso ponto que a 
nanotecnologia assume um grande destaque, em especial no que às nanopartículas diz respeito. 
As nanopartículas fazem parte de uma área da tecnologia farmacêutica que tem vindo 
a ganhar destaque desde há alguns anos. Desde o grande número de combinações de polímeros 
aos mais diversos métodos de produção, passando por novos sistemas que permitem direcionar 
uma determinada molécula para um local de interesse no organismo humano, como os 
dendrímeros ou os nanotubos/nanopartículas de carbono e pelos veículos de composição 
inorgânica como sílica e ouro, a sua utilização disseminou-se desde as áreas de diagnóstico até 
à vertente terapêutica. Não obstante as interessantes propriedades que as caracterizam, as 
nanopartículas têm graves limitações no que concerne à sua estabilidade. De facto, a 
suscetibilidade face a condições ambientais e a dificuldade em mantê-las estáveis em ambientes 
aquosos, levou à conceção do projecto laboratorial que se descreve no presente documento. 
O trabalho laboratorial que foi realizado baseou-se na produção de nanopartículas 
poliméricas de quitosano/sulfato de dextrano (CS/DS) com um rácio de massa de 1:3, ou seja, 
uma molécula de quitosano para três de sulfato de dextrano. Dada a densidade eletrónica 
negativa nos grupos sulfato do sulfato de dextrano, as nanopartículas apresentam um potencial 
zeta negativo. Precisamente por isto é que a reação deste último polímero com o quitosano, 
carregado positiviamente, se realiza de uma forma muito favorável, levando a uma interação 
entre grupos de cargas opostas, que resulta nas nanopartículas. A partir deste ponto, foram 
aplicadas três abordagens de forma a estudar a estabilidade das nanopartículas e propor um 
método eficaz para a preservação das suas características principais – o tamanho e o potencial 
zeta. 
O método aplicado para a estabilização foi a liofilização, que consiste no congelamento 
de amostras das nanopartículas poliméricas e posterior remoção da água congelada por 
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sublimação. Obtiveram-se liofilizados que foram posteriormente reconstituídos, sendo as 
nanopartículas caracterizadas para determinar se o método é realmente eficaz na manutenção 
das características destes veículos. Contudo, e porque o processo de congelamento envolve a 
formação de cristais de gelo que provocam uma disrupção completa destes veículos e posterior 
agregação, estudou-se a capacidade crioprotetora de dois carbohidratos: a glucose e a sacarose. 
Numa primeira abordagem, produziram-se as nanopartículas poliméricas por 
complexação eletrolítica cujas amostras foram concentradas até se atingirem duas 
concentrações distintas: 1 mg/mL e 2 mg/mL. Posteriormente, às amostras foi adicionado o 
carbohidrato que se pretendia estudar – glucose ou sacarose – também a uma concentração 
definida, 5% ou 10% (m/v), caracterizando os veículos antes de se proceder à sua congelação. 
Após este último passo, as amostras foram liofilizadas, reconstituídas e caracterizadas logo 
após a reconstituição. 
Numa segunda abordagem, as mesmas nanopartículas foram produzidas e ajustadas a 
concentrações de 1 mg/mL e 2 mg/mL. Contudo, desta vez, não se procedeu nem à adição do 
carbohidrato nem à sua congelação, permanecendo em suspensão que foi armazenada a 4 ºC 
durante 113 dias. 
Numa terceira abordagem, nanopartículas de CS/DS foram produzidas, foi-lhes 
adiconado o crioprotetor e realizada a caracterização antes do congelamento. Posteriormente, 
foram liofilizadas e armazenadas, à temperatura ambiente, num excicador durante 90 dias. 
Dado que esta última abordagem envolvia o estudo da estabilidade destes veículos na forma de 
liofilizados, de 15 em 15 dias, as nanopartículas foram sendo reconstituídas e caracterizadas, 
em termos de tamanho e potencial zeta, pretendendo-se o estabelecimento de uma relação entre 
a capacidade crioprotetora do carbohidrato utilizado e o tempo de armazenamento das 
nanopartículas. 
Adicionalmente, foi realizado um outro ensaio que pretendeu analisar a influência de 
diferentes ácidos como agentes de solubilização do quitosano e de que forma esses mesmos 
ácidos influenciavam as características fisico-químicas das nanopartículas produzidas. Neste 
ensaio, foram usados 4 diferentes rácios de massa entre os polímeros (quitosano/sulfato de 
dextrano) – 2/1, 3/1, 4/1 e 5/1. Como o quitosano está sempre em maior proporção face ao 
sulfato de dextrano, esperava-se que as nanopartículas resultantes tivessem um potencial zeta 
positivo. 
Dos resultados obtidos no estudo de liofilização, é sugerido que a glucose possui uma 
melhor capacidade crioprotetora face à sacarose. De facto, apesar dos valores de desvio-padrão 
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serem elevados, as médias de variação do tamanho foram, gernericamente, mais próximas de 
1. Relativamente ao potencial zeta, e devido ao facto dos desvios-padrão serem elevados para 
os dois carbohidratos, não foi possível concluir quanto à melhor ou pior capacidade 
crioprotetora da glucose ou da sacarose. É possível assumir que o comportamento dos dois é 
semelhante. 
O estudo em que consistiu esta primeira abordagem de liofilização, foi realizado um 
desenho fatorial, de modo a tentar entender que fatores são os mais preponderantes na 
estabilidade das nanopartículas CS/DS. Os resultados sugerem que é a escolha do crioprotetor, 
neste caso ora a glucose ora a sacarose, que mais influencia a variação nos tamanhos das 
nanopartículas. Quando se considera as variações nos potenciais zeta destes veículos, é 
sugerido que tanto a concentração como o tipo de carbohidrato bem como a interação entre 
ambos, são os fatores preponderantes que influenciam as variações. 
O estudo da estabilidade das nanopartículas quando armazenas em meio aquoso e a 4 
ºC, indicou que até ao dia 50 as características fisico-químicas das nanopartículas mantiveram-
se relativamente estáveis. Contudo, a partir do dia 50 de armazenamento, houve um decréscimo 
notório do seu tamanho em algumas amostras para além de se notar, noutras, uma agregação 
substancial. No que concerne ao potencial zeta, este manteve-se aproximadamente estável ao 
longo dos 113 dias em que decorreu o estudo, mostrando um máximo de 10% de variação nos 
seus valores. 
Por fim fez-se um estudo da estabilidade das nanopartículas após liofilização, tendo-se 
armazenado os liofilizados à temperatura ambiente e em local tendencialmente seco. Os 
resultados sugeriram que é a glucose o carbohidrato que melhor mantém as características 
fisico-químicas das nanopartículas. 
No ensaio que envolveu a solubilização de quitosano em diferentes ácidos, os 
resultados, de uma forma geral, levaram à produção de nanopartículas com tamanho demasiado 
elevado para uma potencial aplicação em administração de fármacos. Além disso, foi notada 
uma tendência incomum no que concerne aos resultados do potencial zeta, que decresceu à 
medida que a quantidade de sulfato de dextrano também diminuiu. De facto, esta tendência 
incomum vai contra o que se esperava: menor presença de sulfato de dextrano, mais carga 
positiva, maior potencial zeta. Assim, concluiu-se ser necessário um estudo mais aprofundado 
para estabelecer uma eventual relação entre o ácido usado como solvente e as características 
finais das nanopartículas. 
  
Chitosan/dextran sulfate nanoparticles: stability evaluation and 
assessment of the effect of different acidic media on nanoparticle preparation 
 
xiii 
 
Abbreviations 
 
ANOVA – ANalysis Of VAriance 
CS – Chitosan 
CV – Coefficient of Variation 
DDS – Drug Delivery Systems 
DS – Dextran Sulfate 
EFSA – European Food Safety Authority 
EMA – European Medicines Agency 
FD – Factorial Design 
FDA – Food and Drug Administration 
PLA – PolyLactic Acid 
PLGA – Poly(Lactic-co-Glycolic) Acid 
SD – Standard Deviation 
TPP – Tripolyphosphate 
WHO – World Health Organization 
  
Chitosan/dextran sulfate nanoparticles: stability evaluation and 
assessment of the effect of different acidic media on nanoparticle preparation 
 
xiv 
 
Figure Index 
 
Figure 1.1 – Schematic representation of the different size scales with the nanoscale and the 
different delivery systems highlighted. Adapted from (14). ...................................................... 3 
Figure 1.2 – Chronological approval of formulations that make use of the encapsulation 
techniques by the Food and Drug Administration (FDA). Adapted from (15). ........................ 4 
Figure 1.3 – Chemical structure of chitin and chitosan. Adapted from (62). ........................... 7 
Figure 1.4 – Dextran sulfate chemical structure. Adapted from (68). ...................................... 9 
Figure 1.5 – The different molecular states that water can adopt when certain conditions are 
met. T represents the water’s triple point. Adapted from (97). ................................................ 11 
Figure 1.6 – Phase diagram for a solution comprised of water and a solute. Teu’ represents the 
eutectic temperature, Tg' the glass transition temperature and Cg’ the maximal freeze 
concentration. Adapted from (94). ........................................................................................... 13 
Figure 3.1 – Schematic representation of (A) nanoparticle production including polymer 
solubilisation and (B) the addition of the cryoprotectant solution to nanoparticle pellets, 
resuspensions step, freezing at -80 ºC, freeze-drying and reconstitution in 1 mL of ultrapure 
water for further analysis. ........................................................................................................ 21 
Figure 4.1 – Dispersion of chitosan after tentative solubilisation in hydrochloric acid (HCl) 
0.001 M. Personal photograph in use....................................................................................... 25 
Figure 4.2 – Nanoparticle cakes obtained after freeze-drying. From left to right: the first three 
were samples freeze-dried with sucrose and the other two, with glucose. Personal photograph 
in use. ....................................................................................................................................... 30 
Figure 4.3 – Normal Q-Q plot for residuals for the size factorial design (FD). ..................... 34 
Figure 4.4 – Pareto plot for the size variation (* means p_value < 0.05). .............................. 35 
Figure 4.5 – Normal Q-Q plot for residuals for the zeta potential factorial design (FD). ...... 36 
Figure 4.6 – Pareto plot for zeta potential variation (* means p_value < 0.05). ..................... 37 
 
  
Chitosan/dextran sulfate nanoparticles: stability evaluation and 
assessment of the effect of different acidic media on nanoparticle preparation 
 
xv 
 
Graphic Index 
 
Graphic 4.1 – CS/DS nanoparticle size variation along time (113 days) upon storage as 
aqueous suspensions at 4 ºC (Di: initial diameter; Df: final diameter). Data represent mean ± 
SD (n = 10). ............................................................................................................................. 28 
Graphic 4.2 – CS/DS nanoparticle zeta potential variation along time (113 days) upon storage 
as aqueous suspensions at 4 ºC (Zi: initial zeta potential; Zf: final zeta potential). Data represent 
mean ± SD (n = 10). ................................................................................................................. 29 
Graphic 4.3 – Size variation of different concentrations of CS/DS nanoparticles upon freeze-
drying, as a function of the used cryoprotectant and its concentration (Di: initial diameter; Df: 
final diameter. Data represent mean ± SD (n = 16). ................................................................ 31 
Graphic 4.4 – Zeta potential variation of different concentrations of CS/DS nanoparticles upon 
freeze-drying, as a function of the used cryoprotectant and its concentration (Zi: initial zeta 
potential; Zf: final zeta potential. Data represent mean ± SD (n = 16). ................................... 32 
Graphic 4.5 – Size variation along time (90 days) of different concentrations of CS/DS 
nanoparticles freeze-dried with glucose, upon storage of the cake at room temperature (Di: 
initial diameter; Df: final diameter). Data represent mean ± SD (n ≥ 4).................................. 38 
Graphic 4.6 – Size variation along time (90 days) of different concentrations of CS/DS 
nanoparticles freeze-dried with sucrose, upon storage of the cake at room temperature (Di: 
initial diameter; Df: final diameter). Data represent mean ± SD (n = 5). ................................ 39 
Graphic 4.7 – Zeta potential variation along time (90 days) of different concentrations of 
CS/DS nanoparticles freeze-dried with glucose upon storage as a cake at room temperature (Zi: 
initial diameter; Zf: final diameter. Data represent mean ± SD (n = 5). .................................. 40 
Graphic 4.8 – Zeta potential variation along time (90 days) of different concentrations of 
CS/DS nanoparticles freeze-dried with sucrose upon storage of the cake at room temperature 
(Zi: initial zeta potential; Zf: final zeta potential. Data represent mean ± SD (n = 5). ............. 41 
 
  
Chitosan/dextran sulfate nanoparticles: stability evaluation and 
assessment of the effect of different acidic media on nanoparticle preparation 
 
xvi 
 
Table Index 
 
Table 4.1 – Number of observations per treatment for the 23 experimental design. 
(“Cryoprotector”: glucose or sucrose; “Cryo_Conc”: cryoprotectant concentration of 5% or 
10%, w/v; “NP_Conc: nanoparticle concentration of 1 mg/mL or 2 mg/mL)......................... 33 
Table 4.2 – Some of the descriptive statistics for each cryoprotector. .................................... 35 
 
  
Chitosan/dextran sulfate nanoparticles: stability evaluation and 
assessment of the effect of different acidic media on nanoparticle preparation 
 
1 
 
1. Introduction 
 
Public health has been, today, one of the most troubling subjects of every government 
all around the world and a constant concern for the World Health Organization (WHO). 
Diseases like AIDS, tuberculosis, Ebola virus disease or the most recent Zika virus infections 
are just the tip of the iceberg in what regards this very complicated matter where the solutions 
are not as obvious and immediate as desired. In the subject of health, Portugal, in 2014, 
dedicated 11.9% of its public budget to Health, being the second most expensive subject after 
the Social Security and Social Actions (1). According to the website PORDATA, which 
displays a series of statistical data regarding the country, in 2014, there were 138.6 elder people 
per 100 younger ones and, not only this is worrying, but also the number keeps increasing (2).  
As time progresses and science improves, it seems natural that life expectancy grows 
accordingly thus being, at this point, of 85.6 years for women and 82.2 for men. Combining 
these numbers with the decrease of natality rates, it is logical that government’s healthcare 
annual budget will be more directed to the elderly specifically on a more dedicated medical 
assistance, an increasing number of nursing homes and, more importantly, the medicine’s 
prices, rather than the younger (3). 
As the human body gets older, there are certain types of complications that tend to 
appear and in order to counteract them, certain molecules are required. It is asked, nowadays, 
a more close relationship between different scientific subjects in order to provide not only new 
molecules with fewer side effects but also new approaches on previously studied drugs. One 
of the most interesting subjects is, probably, the pharmaceutical technology which has a certain 
influence in the various areas of medicine beginning in the production of drugs and finishing 
in their administration to the patient. According to Nogueira Prista et al., pharmaceutical 
technology is the study of the transformation of natural or synthetic products in drugs in order 
to administer them to living beings with the aim of being prophylactic drugs, curative ones or 
simply the diagnostic of certain illnesses (4). It is possible to deduce that this discipline is the 
natural evolution from the concept of Galenic Pharmacy that was used, in the first centuries of 
the current era, to describe the works of Claudius Galenus in the preparation of various 
pharmaceutical forms that the population in general still utilizes, such as the antidotes (4,5). It 
is accepted that when science progresses, its concepts, in many areas, also follow this evolution. 
The vehicles and the administration routes to which it is possible to deliver the molecule that 
has the actual therapeutic effect are two great examples of the said evolution. However, these 
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achievements require investments that, in many occasions, are not possible to conduct by many 
different reasons. 
Since 1960, the pharmaceutical industry in North America has seen a great expenditure 
in research being, by the year of 1990, 8 millions of dollars (6). It is interesting to see that, by 
the final decade of the 20th century, the regulation of the industry itself tightened up, increasing 
to more than 12 years the time necessary to get the approval of a certain drug, which can explain 
that not everything is viable and the loss of money could be immense (6,7). The general 
investment in research is however very high, although lower in Europe comparing with United 
States of America (8), making Europe less competitive (9).  
All around the world, society entered in a century of great challenges especially in the 
pharmaceutical area. Although investments still linger on uncovering new molecules, the 
greater knowledge on how the human organism works allowed the study of other therapeutic 
approaches and, specifically, new pharmaceutical forms (6). Today, they range from 
suspensions and solutions to pills and, interestingly, to the so called drug delivery systems 
(DDS) that make use of a matrix to deliver a certain drug or drugs to a site of interest. Nanosized 
DDS are becoming a reality specially due to the fact that the patient’s well-being and 
consequently, public health, are the cores of the nowadays therapeutic approaches providing a 
safer choice on drug uptake (10–13).  
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1.1. Encapsulation techniques: Nanotechnology as a tool in 
therapeutics 
 
Everything can be categorized by having a form and a size. In Nature, it is possible to 
find animals that are smaller and other ones that are bigger, even in the same species. The same 
happens with objects, which have a wider range of sizes. Before and in the early days of the 
scientific revolution, diseases were taught to be a punishment without a real reason for their 
development. However, that changed when microorganisms were discovered changing the 
paradigm of medicine (5). The therapeutic fields is also changing, going into more molecular 
approaches. Nanostructured DDS, represented in Figure 1.1, may be understood as the 
consequence of that evolution, being in fact believed to entail the future of many treatments 
(14). 
 
 
Figure 1.1 – Schematic representation of the different size scales with the nanoscale and the 
different delivery systems highlighted. Adapted from (14). 
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In a pharmaceutical approach, DDS are vehicles that can carry one or more drug 
molecules, to a specific site or sites in the human organism. In the recent years, DDS have 
grown to get a particularly good spot around the scientific community due to their advantages 
in medicine, healthcare and the global economy. Improvement of drug bioavailability is one of 
the key achievements. By preventing the degradation by certain enzymes, ensuring stabilisation 
or maintaining the therapeutic concentration that is required for the treatment to be successful 
and even the reduction of side effects, the use of drug carriers brought many advantages 
(15,16). 
DDS are mainly used to provide drug protection and there is a variety of materials that 
can be used as matrixes to encapsulate drugs, which explains the wide range of these systems 
that go from liposomes to carbon nanotubes as depicted in Figure 1.1 presented before.  
Figure 1.2 depicts a timeline of drugs approved by the Food and Drug Administration 
(FDA) that use these encapsulating technologies. As the image clearly depicts, even though the 
molecules comprising some of the formulations were discovered and developed almost thirty 
years ago, many are still used these days because they are effective and lead to high patient 
compliance. 
 
Figure 1.2 – Chronological approval of formulations that make use of the encapsulation 
techniques by the Food and Drug Administration (FDA). Adapted from (15). 
 
As depicted by a green arrow in Figure 1.2, there are formulations that use liposomes 
to deliver the active principles. Liposomes are comprised of phospholipids and aside from the 
drugs presented on the image, they can also be used in other therapeutic approaches (17,18). 
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Another approach deserving reference is Abraxane®, which makes use of albumin, a common 
protein in the human organism that helps maintaining the oncotic pressure (19), in order to 
deliver paclitaxel. Highlighted in the orange and blue arrows, there are other formulations that 
use these encapsulating technologies to deliver drugs to a tissue or organ of interest. 
Nanotechnology is a discipline that is very diverse in the approaches that can be used 
on drug delivery, which is increasing in importance and utility (20–24). Many works reported 
the use of nanoparticles as a suitable means for drug targeting using the most diverse 
administration routes. The oral (25–27), parenteral (28,29) and nasal routes (30,31) are widely 
reported alongside the pulmonary route that has been studied intensely for future therapeutics 
(32–35) even though some challenges need to be faced (36,37). Other possible routes such as 
the ocular (38,39) and vaginal (40,41) have also been subject of study for drug targeting using 
nanoparticles. 
Nanoparticles are vehicles which size ranges between 1 nm and 100 nm, although 
vehicles that measure up until 1000 nm are also considered nanoparticles by the majority of 
the scientific community (11,12,14). These nanocarriers are usually characterized by two 
different properties, size and zeta potential. The first defines the dimension of the nanocarrier 
and is highly dependent on the production method and the composition of the vehicle. As for 
the latter, it indicates the surface charge of the nanoparticle and is greatly related to the 
composition of the nanoparticle, to the molecules that are absorbed to the surface of the 
nanocarrier if there is any and lastly, the media where the nanoparticle is being characterized. 
In this regard, the ionic strength and pH are the most important aspects affecting zeta potential 
(42). 
Nanoparticles can also be categorized according to their composition. Metals, lipids 
and polymers are some of the most used materials to compose the matrix of nanoparticles, with 
polymers assuming a position of relevance (43–45). In that case, they are called polymeric 
nanoparticles, being comprised of either synthetic or natural polymers. The most common of 
the used synthetic polymers are poly(lactic-co-glycolic) acid (PLGA) and polylactic acid 
(PLA). The high compatibility, good releasing properties and low toxicity of these polymers 
has enabled their inclusion in several formulations currently approved by the FDA and the 
European Medicines Agency (EMA) (46,47). Additionally, their favourable properties 
potentiates their use in several biomedical applications (48–51). 
In the case of polymeric nanoparticles which matrix derives from natural materials, for 
example chitosan (52), alginate (53), hyaluronic acid (54) and others (55,56), they present a 
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viable approach, even though no pharmaceutical formulation is available in the market making 
use of nanosystems with these components. According to data provided in the literature, 
nanoparticles based on natural polymers also present high biocompatibility, low toxicity and 
good biodegradability (57). Whichever the source of the polymer, the requisites of 
biocompatibility and biodegradability need to be observed for any biomedical approach. 
The knowledge on the different pathological and physiological aspects of the human 
organism is growing day by day. This makes way for the possibility of using some of the harsh 
conditions of the living organisms to favour the action of nanocarriers. That is the case of the 
so called smart polymers (58,59). Nanocarriers comprised of these special polymers are able 
to respond to different physiological conditions (for example, pH, temperature, etc). Many 
variables may be taken into account, but the main message is that these polymers enable a 
controlled and many times targeted release of the encapsulated molecules, thus improving the 
patient’s therapeutics. 
In the following sub-sections, the characteristics of chitosan and dextran sulfate will be 
addressed in detail, as they were the two natural polymers materials used throughout the 
experimental procedures reported in this manuscript. 
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1.1.1. Chitosan 
 
Chitosan is obtained by the N-deacetylation of chitin, a polymer that can be extracted 
from various sources (crustacean’s shells, exoskeletons of certain invertebrates – ladybugs – 
and the cell walls of fungi, for example). It is considered the second most abundant polymer 
on Earth (60), after cellulose (61). However, chitin is not very versatile due to its structure and 
poor solubility in many solvents. Chitin plays a role in the protection of certain animals in 
nature, being organized in semi-crystalline microfibrils to provide the said protection (62). The 
deacetylated form of chitin is chitosan, which structure can be seen on Figure 1.3. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3 – Chemical structure of chitin and chitosan. Adapted from (62). 
 
Chitosan (MW ~30-190 kDa (33,63–65)) is the polymer obtained when deacetylation 
surpasses 50% and is comprised of β (1-4)-links of D-glucosamine and N-acetyl-D-
glucosamine monomers that are distributed randomly throughout the chain. This is the only 
natural polymer exhibiting a cationic character (66). Due to the fact that the amine groups are 
present throughout the structure of chitosan, the more deacetylated the polymer is, the more 
susceptible it is to protonation because nitrogen has an unused pair of electrons that can easily 
interact with electrophilic groups. When chitosan undergoes protonation, which occurs at low 
pH levels, it acquires a positive charge, thus providing the possibility to interact with negatively 
charged groups. This ability has been widely explored in drug delivery, with the preparation of 
nanoparticles by electrostatic interaction, as reported using carrageenan (67), tripolyphosphate 
(TPP) (34) or dextran sulfate (68) as counterions. 
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Chitosan is not soluble in water. Instead, and because the amine groups have a 
logarithmic acidity constant (pKa) of ~6.5 (62), chitosan dissolves easily in acidic media. The 
most usual solvent for its dissolution is 1% (v/v) acetic acid. Due to the fact that the polymer 
is easily protonated, it can also be dissolved in formic and lactic acids and in hydrochloric acid 
solutions (62,69). In a pH of 7 or higher, as the pH is higher than the pKa of amine groups, 
chitosan becomes insoluble, rendering its biologically applications are scarce or non-existent 
(66).  
As mentioned earlier, chitosan presents adequate characteristics regarding biological 
applications (34,37,63,64,70), including biocompatibility, biodegradability and low toxicity. 
Its biodegradability is due to a metabolism by lysozyme (71). Moreover, due to its protonation 
in acidic media, it presents a favourable interaction with mucus (72), which is particularly 
relevant in the intestine, where there is a high amount of mucus. This is actually one of the 
reasons justifying its application in specific disease conditions, such as  colonic inflammation 
(27). Nevertheless, the description of chitosan applications in literature is endless, including 
pulmonary and oral insulin delivery (25,37) as well as the delivery of antibiotics and small 
genetic fragments (73–75), just to mention some examples.  
Finally, chitosan can also be found in a variety of dietary supplements (Lipoforte® and 
EasySlim® Blocker, just to name a few) for weight loss. However, the European Food Safety 
Authority (EFSA) considers that there is not enough evidence that supports this indication (76). 
There are other studies that report its beneficial use on lowering LDL-cholesterol (77,78), a 
claim that EFSA found to have enough evidence that supports it. However, some problems 
have also been described for supplements, reporting chitosan interference with certain 
treatments, for example, anticoagulation therapy with warfarin (79) and anti-epilepsy therapy 
with valproate (80).  
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1.1.2. Dextran sulfate 
 
Dextran sulfate was the other polymer used in this experimental work. It is also a natural 
polymer, obtained from bacteria of the Leuconostoc genus. It is comprised of a branched 
anhydroglucose backbone with attached sulphur groups, the latter believed to be 17% of the 
total mass of the polymer. This means that, 2.3 sulphur groups are present for each glucosyl 
residue, thus the polymer being expected to be negatively charged (32,63,68). Its chemical 
structure can be seen in Figure 1.6. 
 
 
 
 
 
 
 
 
Figure 1.4 – Dextran sulfate chemical structure. Adapted from (68). 
 
Dextran sulfate (MW ~5-500 kDa (70,81–83)) is also reported as biocompatible and 
biodegradable (84), thus theoretically complying with mandatory requisites for biomedical 
applications. Studies regarding the use of dextran sulfate as a component of DDS are scarce, 
even though it was widely studied in the eighties for its anti-HIV activity, against HIV-1. Its 
mechanism of action, in this context, involves inhibiting the reverse transcriptase, a viral 
enzyme responsible for turning the viral RNA in viral DNA that will, ultimately, be part of the 
host cell DNA resulting in the production of viral particles (82,85,86). Additionally, dextran 
sulfate has also been shown to activate macrophages by establishing an interaction with the 
scavenger receptor present in these cells (87). Moreover, regarding the immune system, it is 
believed that dextran sulfate induces activation of B lymphocytes even though that mechanism 
is mediated by macrophages (88). Another aspect that is widely mentioned in studies is an 
anticoagulant capacity similar to heparin, even though it wasn’t studied further (68,70,89). 
Finally, dextran sulfate is used, nowadays, to induce colitis in mouse models (90,91). 
Approved formulations containing this polymer include two EMA-approved orphan 
medicines: i) a medicine for the prevention of graft rejection and its further damage on 
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pancreatic transplantation by inhibiting the activation of complement system and clotting (92) 
and ii) a medicine to promote mobilisation of progenitor cells, prior to stem cell transplantation, 
through a cytokine released by bone marrow that can guide these important cells through blood 
stream  (93). 
Dextran sulfate is a very interesting polymer with many characteristics that can be used 
in drug delivery. However, there is still much work to do and, more importantly, study possible 
associations with other polymers to produce nanocarriers with a potential use in therapeutics.   
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1.2. The freeze-drying process 
 
As mentioned previously, nanoparticle’s stability is an issue that may compromise the 
use of these systems. Problems of aggregation that result in the increment of particle’s size are 
the most common limitation (36). Moreover, as many nanoparticle formulations are produced 
in aqueous environment, their direct storage is not feasible for long periods of time as there is 
high probability of contamination by microorganisms which, ultimately, may affect the 
stability of the nanosuspension (94). It is thus important to carefully control the conditions of 
production and storage of nanocarriers. Considering that stability issues in suspensions may 
prevent the clinical use of nanoparticles as DDS, the description of stabilisation processes has 
been increasing. 
Freeze-drying, alongside supercritical fluid drying (95), has been described as one of 
the most adequate techniques to stabilise nanoparticles produced in aqueous environment (96). 
Water may exist in various states that can be characterized by the organization of its molecules: 
solid, liquid and gas. This plasticity is one of the cores of the process of freeze-drying. The 
different states that water can adopt are presented in Figure 1.7, where the specific conditions 
that need to be settled in order to produce a change in water’s state are also referred (97). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 – The different molecular states that water can adopt when certain conditions are 
met. T represents the water’s triple point. Adapted from (97). 
Chitosan/dextran sulfate nanoparticles: stability evaluation and 
assessment of the effect of different acidic media on nanoparticle preparation 
 
12 
 
 
When temperature is 0.01 ºC (or 273.16 K) and pressure is 0.006 atm (or 6.12 mBar), 
the so called triple point is met, with water assuming the three states simultaneously. So, in 
order to ensure the process of sublimation (transformation of water in solid state to the gas 
state) water needs to meet conditions of temperature and pressure that are below those of the 
triple point (97). When a frozen suspension of nanoparticles is subject to these conditions, ice 
sublimates and the remaining residue corresponds uniquely to nanoparticles.  Theoretically, the 
solid state provides better stability than the aqueous analogue (6). 
The process of freeze-drying is comprised of three different steps: freezing, primary 
drying and secondary drying. The freezing step is the first and it has to be considered differently 
than just the freezing of water, as the colloids act like a solute. When water freezes, molecules 
tend to form crystals, which will have a more amorphous structure if freezing is rapid or almost 
instantaneous. Due to this fact, after freeze-drying, the resulting cake will be very porous due 
to the empty spaces left by the ice crystals once formed thus being, its reconstitution, easier. 
On the other hand, if freezing is slow, a more organized structure will be formed because ice 
crystals have time to grow and form a more organized crystalline net, resulting in a more dense 
cake which reconstitution will be more difficult to achieve (94,98). The first process occurs 
when liquid nitrogen is used, while the second results from the use of a freezer, which has far 
higher temperature than liquid nitrogen (99). Whichever is the method selected to freeze the 
colloidal suspension, ice crystals will be formed. The unoccupied spaces between these crystals 
will be filled with the solute (nanoparticles in this case) that will be “trapped”, resulting in a 
more concentrated solution. As the solution experiences an even lower temperature, the more 
concentrated and viscous it gets, reaching a temperature where it finally freezes, named eutectic 
temperature (Teu). It is in this process that cryoprotectants have a relevant role to play. 
Cryoprotectants are excipients used to provide protection to a certain product from the stress 
that it undergoes upon/during freezing (98). Carbohydrates such as sucrose and glucose are of 
the most used cryoprotectants and have been proposed for the stabilisation of nanoparticles 
(100–102). These sugars, when added to colloidal suspensions and are subjected to freezing, 
inhibit the formation of big and fully developed ice crystals by reducing their nucleation and 
so, as the temperature goes even lower, water will keep freezing and the solution gets even 
more concentrated and viscous, as said before. At some point, freezing will stop, reaching a 
new temperature, the glass transition temperature (Tg’) where, in this state, the sample is 
vitrified or glassified. This state is characterized by a solid solution where the solutes 
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(nanoparticles and sugar) are concentrated (Cg
’) with unfrozen water. The latter is associated 
with the solid solution and so, it will only be removed in the third step of the freeze-drying 
process, if this takes place. The water that managed to freeze, thus forming very small ice 
crystals, will be removed in the step of primary drying, to be mentioned next (94,96). All these 
processes are depicted in graphical form, in Figure 1.6.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6 – Phase diagram for a solution comprised of water and a solute. Teu’ represents the 
eutectic temperature, Tg' the glass transition temperature and Cg’ the maximal freeze 
concentration. Adapted from (94). 
 
The freezing step, even though it is the first step, represents the most critical phase of 
freeze-drying. This is because it is when all molecular changes occur and, consequently, the 
phase where the cryoprotectant capacity of different components can be studied.  
The step of primary drying occurs under vacuum. After a first step of low temperatures 
(between -30 ºC and -50 ºC (94,103,104)), the temperature raises when primary drying starts, 
in order to allow sublimation of ice and the consequent elimination of water from the samples. 
From this step, it is originated a rather porous material inside the reservoir where samples were 
stored. The duration of this phase is directly related to two aspects: the proper formulation and 
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the vial where the sample is inserted (94). The first aspect is related to the volume of solvent 
comprising the formulation (naturally, a colloidal suspension that has 1 mL will dry more 
rapidly than one that has 10 mL). Also, this drying is directly related to the capacity of water 
extraction of the equipment, so, small samples require less time to dry. The second aspect refers 
to the format of the vial. If it is large and deep, the drying will take longer time to be effective 
than if the vial is narrow and has little depth like an Eppendorf tube. When primary drying 
ends, some solvent will still be retained in the sample (about 15% - 20%), remaining bound to 
the solid sample (96). 
The third step of the process is the secondary drying. This is an optional step and is just 
intended to dry the solvent that is bound to the formulation, which did not freeze, as explained 
above. This phase involves more severe vacuum conditions, meaning that the pressure inside 
the equipment will be lower, while the temperature will be higher to allow the elimination of 
the remaining water. However, this final step will only remove about 5-10% of the bound 
solvent and so, final freeze-dried formulations will still be comprised of, at least, 5% of 
humidity (6). Although optional, performing this final step is beneficial for the formulation due 
to the fact that, by removing the excess of water that is bound to it, the damaging long-term 
effects of water will be reduced (105).  
As it was mentioned above, the freeze-drying process is one possible way to overcome 
stability problems of colloidal suspensions. However, and due to the fact that ice crystals (small 
or large) are formed upon freezing, this could seriously damage the polymeric vehicles that 
were produced. In fact, if nanoparticles are frozen without a component that protects them from 
ice crystal formation, the polymeric vehicles will disrupt and naturally aggregate. During 
freeze-drying, the aggregates will produce a sediment comprised of carriers which size is very 
far from the nanoscale, an occurrence only noticeable upon reconstitution. The use of 
cryoprotectants to protect polymeric nanoparticles during freeze-drying, and particularly 
during the freezing step, has long been studied. Cryoprotectants will fill the spaces between the 
nanocarriers inhibiting the production of ice crystals or the formation of small-sized crystals. 
Due to the different chemical structures that different carbohydrates present, the final cakes 
that result from freeze-drying may also look very different. 
Nowadays, there are several studies reporting the use of freeze-drying as a possibility 
to stabilise nanocarriers with therapeutic value: i) Cerdeira et al. refer to freeze-drying of 
miconazole and itraconazole nanosuspensions (106); ii) Soares et al. study the viability of 
insulin-loaded solid lipid nanoparticles (100); iii) Hafner et al. suggest lechitin/chitosan 
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nanoparticles for the delivery of lipophilic drugs (107). Many other works consider freeze-
drying as a valuable technique to overcome nanoparticle’s stability problems (51,108,109).  
However, some limitations have also been identified. One of them concerns the 
possibility of particle aggregation during the process of freeze-drying, which is only confirmed 
upon reconstitution of the system. Another limitation is related with the used equipment and 
whether it may allow secondary drying. If this is not performed, the amount of humidity 
associated may, at long-term, lead to microorganism growth, which is further potentiated by 
the presence of carbohydrates. Finally, another limitation of this process refers to the proper 
components of the lyophilizates, as some molecules are more susceptible to degradation, such 
as proteins (110). 
Although nanocarrier stability is still an issue, many are the works addressing this 
aspect. With the advances of medicine and chemistry, it is believed that in some years more 
formulations containing these carriers will become available. Therefore, ensuring their long-
term stability is a relevant matter, worth of research investment. 
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2. Objectives 
 
This work was established within a wider research line being developed in the Drug 
Delivery Laboratory regarding the preparation of polysaccharide nanoparticles. The specific 
aim of the work was to study the stabilisation of chitosan/dextran sulfate (CS/DS) 
nanoparticles, which were previously developed by the group. In this regard, the technique of 
freeze-drying was used and the capacity of two different sugars, glucose and sucrose, to work 
as cryoprotectants in the process was tested. Both the short- and the long-term stability of 
reconstituted vehicles were evaluated, determining their size and the zeta potential immediately 
after the process and upon 3 months of storage at room temperature in a desiccator. 
 Additionally, a study was conducted to verify the effect of different acidic media (acetic 
acid 1%, hydrochloric acid (HCl) 0.1 M and 0.01 M) to dissolve chitosan on the final 
characteristics of CS/DS nanoparticles. 
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3. Materials and Methods 
 
The work presented in this memory refers to the preparation and stabilisation of CS/DS 
nanoparticles. An important part of the work was based on an experimental design, a very 
important tool in science that allows researchers to obtain results with statistical significance. 
That is the part referring to the study of nanoparticle stabilisation by freeze-drying, in which 
different conditions were approached to produce a dry and stable formulation that permitted 
the preservation of nanoparticle physicochemical characteristics.  
Additionally, a study was also performed to evaluate the effect of different acidic media 
used to dissolve chitosan, on the final physicochemical characteristics of CS/DS nanoparticles. 
 
3.1. Reagents 
 
Chitosan-base (low molecular weight, deacetylation degree ≥ 75-85% (111)) and 
dextran sulfate sodium salt from Leuconostoc spp. were purchased from Sigma-Aldrich® 
(Germany). Glucose, sucrose and hydrochloric acid 37% were purchased from VWR 
Chemicals® (Portugal). Glacial acetic acid was purchased from Fisher Scientific® (United 
Kingdom). Ultrapure water (Millipore®, Portugal) was used throughout. All other chemicals 
were reagent grade. 
 
3.2. Preparation of CS/DS nanoparticles 
 
CS/DS nanoparticles were prepared by polyelectrolyte complexation, in which the 
negatively charged sulfate groups of DS interact with the positive regions of CS (amino 
groups), leading to the production of nanoparticles as a result of the interactions that are 
established between these two polymers.  
 
3.2.1. Study of the effect of different acidic media to 
dissolve chitosan 
 
In order to determine the effect of different acidic media used to dissolve chitosan on 
nanoparticle characteristics, a study was performed using 1% (v/v) acetic acid and HCl at the 
concentrations of 0.01 M and 0.1 M. While chitosan solution (1 mg/mL) prepared in acetic acid 
had a pH of 2.88, those prepared in HCl had 2.26 (0.01 M) and 1.04 (0.1 M), respectively. To 
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allow meaningful comparisons, nanoparticles were produced at different CS/DS mass ratios 
(2/1, 3/1, 4/1 and 5/1). A stock solution of DS (1 mg/mL, pH 7.32) was prepared using ultrapure 
water, which was then diluted to the specific concentrations needed to respect the previously 
established ratios. All stock solutions were filtered (0.45 µm) before use. CS/DS nanoparticles 
were also spontaneously formed when 0.8 mL of the DS solution were added to 2 mL of CS 
solution (1 mg/mL), under magnetic stirring at room temperature, for 10 minutes. Nanoparticle 
suspensions were then transferred to Eppendorf tubes, onto a 10 µL glycerol layer and isolated 
by centrifugation at 16000 g, at 15 ºC, for 30 minutes (Thermo Scientific®, Germany). The 
supernatants were discarded and the pellet was resuspended in 200 µL of ultrapure water. 
 
3.2.2. Freeze-drying study 
 
Considering a previous work performed by the team, it was established that CS/DS 
nanoparticles of mass ratio 1/3 were those to perform in the present study. CS was dissolved in 
acetic acid at 1% (v/v) at a concentration of 0.83375 mg/mL. DS was dissolved in ultrapure 
water at a concentration of 1 mg/mL. All stock solutions were filtered (0.45 µm) before use 
and their pH determined. CS/DS nanoparticles were spontaneously formed when 0.8 mL of the 
CS solution were added to 2 mL of DS solution, under magnetic stirring, at room temperature. 
Stirring was maintained for 10 minutes. After this, the pH of nanosuspensions was determined 
and these were transferred to Eppendorf tubes, onto a 10 µL glycerol layer and isolated by 
centrifugation at 16000 g, at 15 ºC, for 30 minutes (Thermo Scientific®, Germany), as described 
in Figure 3.1A. After the centrifugation step, the supernatants were discarded and the pellet 
was resuspended in 200 µL of cryoprotectant solution, as depicted in Figure 3.1B.  
Two control experiments were performed: one consisted in simply producing 
nanoparticles, resuspending in water and storing at 4 ºC, performing a monitorisation of size 
and zeta potential along time; the other comprised the production of nanoparticles, 
resuspension in water and freeze-drying (in absence of cryoprotectants). 
 
3.3. Evaluation of cryoprotectants for nanoparticle stabilisation 
during freeze-drying 
 
After production of the nanoparticles as described above (section 3.2.2.), the dispersion 
of nanoparticles upon resuspension to produce nanoparticle concentrations of either 1 mg/mL 
or 2 mg/mL (see Annexes A1.1 and A1.2). Sucrose and glucose were tested separately as 
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cryoprotectants, being used at the concentrations of 5% and 10% (w/v). Nanoparticle 
suspensions and the cryoprotectant solutions were mixed to obtain a final volume of 1 mL, 
which was frozen at -80 ºC and then freeze-dried under the following conditions: pressure of 
(3.9 to 4.9) x 10-5 atm (or 0.04-0.05 mBar) and 72 h of primary drying starting at -49 ºC 
(Labconco® FreeZone 6 Liter Benchtop Freeze Dry System freeze dryer, Labconco®, USA). 
After freeze-drying, nanoparticles were reconstituted in the same volume of ultrapure water as 
that initially comprised the nanoparticle suspension submitted to freeze-drying (1 mL), and 
their size and zeta potential determined.  
The same freeze-drying approach was performed with the control experiment 
mentioned earlier (freeze-drying of nanoparticle suspension in absence of cryoprotectant). 
Additionally, freeze-dried samples were also stored at room temperature in a desiccator 
for 90 days. With intervals of 15 days (day 1 corresponded to the end of freeze-drying), samples 
were reconstituted with ultrapure water (1 mL) and size and zeta potential characterised. 
 
3.4. Characterisation of nanoparticles 
 
3.4.1. Physicochemical properties 
 
From every sample prepared, before and after freeze-drying, a 20 µL aliquot was 
extracted and diluted in 1 mL of ultrapure water. Afterwards, this suspension was placed on an 
electrophoretic cell and the size and zeta potential analysed by photon correlation spectroscopy 
and laser Doppler anemometry, respectively, using a Zetasizer Nano ZS (Malvern Instruments, 
Malvern, UK), at 25ºC. 
 
3.4.2. Nanoparticle production yield 
 
The nanoparticle production yield was determined by gravimetry. For this purpose, 
nanoparticles were produced according to the procedure described previously, and after 
centrifugation, the nanoparticle suspension was freeze-dried over 72 h, using a Labconco® 
freeze dryer (Labconco® FreeZone 6 Liter Benchtop Freeze Dry System freeze dryer, 
Labconco®, USA). The production yield was determined in three different assays (n ≥ 10) and 
was calculated as follows:  
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𝑃𝑌 (%) =
𝑛𝑎𝑛𝑜𝑝𝑎𝑟𝑡𝑖𝑐𝑙𝑒 𝑤𝑒𝑖𝑔ℎ𝑡
𝑡𝑜𝑡𝑎𝑙 𝑠𝑜𝑙𝑖𝑑𝑠 𝑤𝑖𝑒𝑔ℎ𝑡
 × 100 
 
where “nanoparticle weight” represents the weight of said vehicles after freeze-drying and 
“total solids weight” is the total amount of solids used to produce nanoparticles which are, in 
this particular case of unloaded nanoparticles, chitosan and dextran sulfate. 
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Figure 3.1 – Schematic representation of (A) nanoparticle production including polymer 
solubilisation and (B) the addition of the cryoprotectant solution to nanoparticle pellets, 
resuspensions step, freezing at -80 ºC, freeze-drying and reconstitution in 1 mL of ultrapure 
water for further analysis. 
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3.5. Statistical methodology 
 
The following section describes the statistical methodologies used throughout this 
work. 
The approach of evaluating nanoparticle stabilisation by means of freeze-drying and 
immediate reconstitution and characterisation was performed according to a statistical 
technique named Factorial Design (FD). This methodology is widely used in manipulative 
experiments where it is necessary to study the joint effect of the factors on a response. This is 
an experimental strategy in which factors are varied together, instead of one at a time (112). 
The objective of this factorial experiment was to investigate the influence of three factors (X1, 
X2, X3) on the response variable (Y) that consists in nanoparticle stability after freeze-drying. 
Therefore, a 23 experimental design (8 treatments) was used, where 3 is the number of factors 
in the design and 2 refers to the number of levels for each factor. The 23 design is particularly 
useful in the initial phase of the experimental work, when many factors are investigated. 
The FD was planned with equal number of observations within each treatment, which 
is designated as a balanced design. The response of a 23 experimental design can be written as 
𝑌 = 𝑋1 + 𝑋2 + 𝑋3 + (𝑋1 ∗ 𝑋2) + (𝑋1 ∗ 𝑋3) + (𝑋2 ∗ 𝑋3) + (𝑋1 ∗ 𝑋2 ∗ 𝑋3), 
where Y is the design response measured during the experiment, X1, X2, X3 are the main factors, 
and the remaining terms are the 2-order interactions and the 3-order interaction. The linear 
model associated is the following,  
𝑌 = 𝛽0 + 𝛽1𝑋1 + 𝛽2𝑋2 + 𝛽3𝑋3 + 𝛽4(𝑋1 ∗ 𝑋2) + 𝛽5(𝑋1 ∗ 𝑋3) + 𝛽6(𝑋2 ∗ 𝑋3) + 𝛽7(𝑋1 ∗ 𝑋2 ∗ 𝑋3) + 𝜀 
where β0 is the intercept, βi, i = 1…7 are the linear model coefficients, and ε is the error 
component. 
Furthermore, after adjusting a FD, the basic assumptions to be checked are that the 
errors are independent, normally distributed and have constant variance (homogeneity). A 
graphical approach (Q-Q plot) is used for the inspection of the normality, where the values 
should appear in to the straight line, and the Levene’s test is used to test the equality of 
variances of the samples. In practice, inspection of the residuals (errors’ estimates) is an 
important issue, since violations of the model adequacy and basic assumptions can be detected. 
Besides the underlying assumptions, a careful analysis was performed for unusual and 
influential data. These observations can be detected through the inspection of the standardized 
and studentized residuals, and also by measuring influence with Cook’s statistic (112,113). 
In experiments involving 2k factorial designs, it is important to examine the magnitude 
and direction of the factor effects to determine which are more important for the case study. 
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The pareto plot allows to compare the effects of each one of the factors against each other. The 
absolute values of the model parameters are plotted from the largest to the smallest magnitude. 
These coefficients are the exact coefficients from the linear model. The R function paretoPlot() 
from package pid (114) was used. 
The statistical analyses, in section 4.3.3, were performed with SPSS (version 24.0 for 
windows) and with R software (115). Statistical significance is reached whenever p_value is 
less than α = 5%, the level of significance used in all the performed analysis. 
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4. Results and Discussion 
 
In the following chapter, the results obtained through the experimental procedures 
aforementioned are presented and discussed. 
 CS/DS nanoparticles were successfully obtained by a polyelectrolyte complexation 
process, using conditions previously established by the research group. The formation of 
nanoparticles was confirmed by the Tyndall effect occurring after the mixture of the two 
polymeric solutions, where by emitting a light through the suspension enabled the observation 
of slight turbidity. 
 
4.1. Effect of different acidic media to dissolve chitosan on 
CS/DS nanoparticle characteristics 
 
Chitosan-based nanoparticles have long been proposed in the field of drug delivery. 
When chitosan base is used, as in this study, the most common approach is to perform its 
solubilisation in acetic acid, although other acids could be used. On the other side, when a salt 
of chitosan is used, the most reported molecule is chitosan hydrochloride. In this manner, it 
was decided to test HCl as a second possibility to solubilise chitosan base. The objective of the 
study was to verify if a different acid could translate into different physicochemical 
characteristics of nanoparticles. 
The tested solvents were: 1% (v/v) acetic acid, HCl 0.1 M, 0.01 M and 0.001 M. 
However, because the amine groups have a pKa of ~6.5 (62), resulting in an acidity constant 
(Ka) of ~3.16 x 10
-7, and the pH of 0.001 M HCl solution is ~3, the acid is not strong enough, 
in this case, to protonate the polymer and provide the solubilisation (62,69). Therefore, under 
these conditions, chitosan remains undissolved, as can be observed in Figure 4.1, preventing 
its use to produce nanoparticles. 
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Figure 4.1 – Dispersion of chitosan after tentative solubilisation in hydrochloric acid (HCl) 
0.001 M. Personal photograph in use. 
Three different media were, thus, finally used to solubilise chitosan and, subsequently, 
to prepare CS/DS nanoparticles. These were produced at mass ratios of 2/1, 3/1, 4/1 and 5/1. 
Acetic acid at 1% and HCl 0.01 M produced nanocarriers, although with sizes greater 
than 500 nm (data not shown), which in many times considered the limit of size adequate for 
drug delivery applications, namely if mucosal delivery is envisaged (116,117). The use of HCl 
0.1 M demonstrated to not be feasible for the purpose of nanoparticle production, although the 
polymer efficiently dissolved chitosan. In fact, the sizes obtained for the nanoparticles were 
very high (> 1250 nm), and far from the nanometre range. Zeta potential was positive in all 
formulations but demonstrated unexpected behaviour, although it was consistent when any of 
the three acids were applied. In this regard, it was observed that, for a constant, amount of CS 
present in each formulation, the zeta potential became less positive with the decrease of DS 
(data not shown). 
Charge ratios of the produced CS/DS nanoparticles were calculated. The theoretical 
mass ratios of 2/1, 3/1, 4/1 and 5/1 mean (in theory) that there will be present 2, 3, 4 and 5 
more chitosan mass comparing with dextran sulfate, respectively. The supplier reports per 
glucosyl residue of dextran sulfate 2.3 sulphur groups (118), while for chitosan, 1 deacetylated 
residue equals to one positive charge (when protonated). The used chitosan has 80% 
deacetylation (a mean of the interval mentioned in section 3.1) which means that, considering 
the monomeric polymer weight ratio of 169 g/mol (119) and the mass contained in the 
formulation, there are present ~9.47 x 10-6 positive charges in the media. As for dextran sulfate, 
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considering 2.3 negative charges per glucosyl residue, the monomeric polymer weight of 484 
g/mol (68) and also depending on mass weighted to produce the stock solution and further 
dilutions, there are present ~4.75 x 10-6 negative charges for a CS/DS ratio of 2/1, ~3.17 x 10-
6 negative charges for a CS/DS ratio of 3/1, ~2.37 x 10-6 negative charges for a CS/DS ratio of 
4/1 and ~1.90 x 10-6 negative charges for a CS/DS ratio of 5/1. Therefore, the (+/-) charge ratio 
for CS/DS nanoparticles 2/1 (w/w), 3/1 (w/w), 4/1 (w/w) and 5/1 (w/w) are, respectively, 1.99, 
2.99, 3.99 and 4.98. This indicates a clear predominance of positively charged groups in all 
cases, which is coincident with the overall positive zeta potential that was obtained (between 
+15 and 52 mV). However, it also reinforces that nanoparticles of mass ratio 5/1 should have 
a higher positive charge than 2/1, which was not observed in any case.  
Due to time constraints, it was not possible to further replicate and widen the assay. It 
is however considered that this would be helpful to make the results more consistent and 
provide some explanations, apart from permitting drawing conclusions about the real effect (or 
absence of it) of using different acidic media to dissolve chitosan. In further studies, a new 
experiment could be designed with not only a higher number of samples but also with 
optimized conditions so that objective conclusions could be drawn. 
 
4.2. Production of CS/DS nanoparticles for the freeze-drying 
stability study 
 
Nanoparticle’s stability is a major concern due to their particular characteristics already 
discussed in previous sections. Moreover, the proper conditions of preparation and the handling 
of nanoparticles are yet other aspects requiring attention. Due to their rather particular 
characteristics, nanoparticles are very susceptible to external weather and to the laboratory 
environment. Atmospheric conditions are very difficult to control in the academic environment, 
as there is no such a controlled infrastructure, causing variations on humidity and temperature 
that can affect nanoparticle preparation. In spite of the use of air-conditioning, the conditions 
cannot always be maintained unaltered. 
As referred in the methodology, CS/DS nanoparticles were prepared in a previous work 
of the team and the formulation corresponding to CS/DS mass ratio of 1/3 was the one selected 
to perform the present work of studying the effect of cryoprotectants in nanoparticle freeze-
drying. Size and zeta potential were the properties used to characterise and evaluate CS/DS 
nanoparticles throughout the work. Size consists of a measurement of the hydrodynamic 
diameter of the nanoparticle, while zeta potential entails the measurement of its surface charge. 
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Considering the selected CS/DS mass ratio of 1/3, there will be three molecules of dextran 
sulfate per each chitosan molecule. Therefore, the net charge of these nanoparticles is expected 
to be negative, although that depends on the charge density of the polymers. The 
physicochemical characteristics of freshly prepared CS/DS nanoparticles (1/3, w/w) were 
determined to be 270 ± 50 nm and -44.8 ± 4.5 mV, which can be considered adequate for drug 
delivery purposes, from a general point of view (116). 
Although most works devoted to drug delivery categorise nanoparticle formulations 
according to polymeric mass ratios, charge ratios seem to have a greater importance in 
nanocarriers formed by electrostatic interaction. As referred in section 4.1, the mass of each 
monomer of the polymers involved in the process was converted to moles of charge. Therefore, 
and considering both the polymer masses in the formulation, the monomeric polymer weight 
and the polymeric mass ratio (see methodology), chitosan has ~3.95 x 10-6 positive charges, 
while dextran sulfate has ~9.50 x 10-6 negative charges. For a CS/DS mass ratio of 1/3, the (+/-
) and (-/+) ratios are, respectively, 0.33 and 3.01, indicating a higher abundance of negatively 
charged groups. This is in line with the registered zeta potential around -45 mV. Another work 
describing the preparation of CS/DS nanoparticles reported results that are in line with those 
described herein (120). In that case, for a CS/DS mass ratio of 1/2 a (-/+) ratio of 2.24 was 
indicated, while a mass ratio of 1/4 resulted in a charge ratio of 4.48. This is merely indicative, 
as the number of charges will be strictly dependent on the type of chitosan. The (-/+) ratio 
indicated for the nanoparticles of the present work (3.01) perfectly fits the trend reported in the 
mentioned study. 
 
4.3. Evaluation of the stability of CS/DS nanoparticles 
 
4.3.1. Evaluation of the stability of an aqueous suspension 
of CS/DS nanoparticles at 4 ºC  
 
Nanoparticles are usually produced in aqueous environment and, as referred in the 
introduction, this raises a concern on their long-term storage, as aggregation is frequently 
mentioned to occur (98,121,122). In this work, an assay was conducted to evaluate the 
evolution of nanoparticle physicochemical characteristics (size and zeta potential) along time, 
upon storage of the aqueous suspension of nanoparticles at 4 ºC (nanoparticles were simply 
resuspended in water). The study lasted 113 days and the results are presented in Graphics 4.1 
(size) and 4.2 (zeta potential). 
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Graphic 4.1 – CS/DS nanoparticle size variation along time (113 days) upon storage as 
aqueous suspensions at 4 ºC (Di: initial diameter; Df: final diameter). Data represent mean ± 
SD (n = 10). 
 
As depicted in Graphic 4.1, at both concentrations nanoparticles maintained their size 
relatively stable in the first 43 days, as size variation was around 1. Approximately from day 
50 on, a certain decrease of size was observed independently of the concentration, remaining 
consistent until the end of the assay. These variations were of approximately 20-30%, but they 
are devoid of statistical significance, due to considerably high standard deviations. 
Concerning the results of zeta potential (Graphic 4.4), the general observation is that 
the parameter remained approximately stable, with 10% maximum variation between the 
beginning and end of the assay. 
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Graphic 4.2 – CS/DS nanoparticle zeta potential variation along time (113 days) upon storage 
as aqueous suspensions at 4 ºC (Zi: initial zeta potential; Zf: final zeta potential). Data represent 
mean ± SD (n = 10). 
 
The ability to maintain the stability of physicochemical characteristics of aqueous 
suspensions of polysaccharide-based nanoparticles stored at 4 ºC has been referred in several 
occasions (33,67,103,123,124). However, this does not prevent the need to find other strategies 
for the long-term storage of nanoparticles, as contamination by microorganisms remains a 
potential problem not addressed in the study above and there are also the concerns about 
transportations costs, which are higher for liquids. Therefore, approaching strategies for the 
production of dry formulations of nanoparticles is a real need, which will be addressed in the 
next section. 
 
4.3.2. Effect of cryoprotectants in the physicochemical 
characteristics of the CS/DS nanoparticles 
 
Freeze-drying has been frequently described as adequate methodology for the objective 
of improving nanoparticle stability and obtaining solid-state nanoparticle formulations. 
However, colloidal carriers may undergo different stresses during freeze-drying, which can 
alter their characteristics. Cryoprotectants are, thus, frequently used to overcome that 
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limitation. In this context, glucose and sucrose were evaluated in this study as cryoprotectants 
for the stabilisation of CS/DS nanoparticles during freeze-drying. 
A control assay was conducted in which CS/DS nanoparticles were resuspended in 
ultrapure water, then frozen and submitted to freeze-drying in the absence of cryoprotectants. 
After the reconstitution with ultrapure water, sediment was visible on the bottom of the tube. 
This is possibly due to the lack of cryoprotectant, which did not prevent the growth of ice 
crystals, causing nanoparticle disruption and aggregation, as explained in the introduction (36). 
These observations constituted a baseline for the assay in which carbohydrates (glucose and 
sucrose) were used as cryoprotectants. After freeze-drying with cryoprotectants and before any 
reconstitution was performed, the aspect of the cakes was registered, being depicted in Figure 
4.2. 
 
 
 
 
 
 
 
 
 
Figure 4.2 – Nanoparticle cakes obtained after freeze-drying. From left to right: the first three 
were samples freeze-dried with sucrose and the other two, with glucose. Personal photograph 
in use. 
 
The figure demonstrates clear differences in the formed cakes depending on the use of 
glucose or sucrose. Sucrose produced a cake with a cotton candy-like texture, while glucose 
cakes resemble a transparent caramel texture. These differences certainly result from different 
chemical structures of the carbohydrates. Sucrose cakes were thus more porous, favouring 
reconstitution. In turn, cakes resulting from glucose had harder reconstitution, but it was 
completed with success. As mentioned on section 3.3, the freeze-drying equipment was only 
able to perform a primary drying, theoretically eliminating approximately 80% of the total 
water contained in the samples. Therefore, in order to further stabilise the samples before 
reconstitution and subsequent characterisation, they were put into a desiccator for at least 72 h. 
The results of size variation of CS/DS nanoparticles are shown in Graphic 4.3. 
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Graphic 4.3 – Size variation of different concentrations of CS/DS nanoparticles upon freeze-
drying, as a function of the used cryoprotectant and its concentration (Di: initial diameter; Df: 
final diameter). Data represent mean ± SD (n = 16).  
 
Keeping in mind that an ideal variation would correspond to 1, meaning that 
reconstituted nanoparticles maintained the initial characteristics, the results suggest a better 
performance of glucose as a cryoprotectant, when size is the focused characteristic. In that case, 
a maximum variation of 1.1 ± 0.4 was obtained at nanoparticle concentration of 2 mg/mL and 
5% (w/v) glucose. Nevertheless, the standard deviations were considerably high, thus 
preventing more concrete conclusions. For sucrose, the maximum variation was registered 
again for 2 mg/mL and 5% (w/v) being of 1.3 ± 0.3. Additionally, considering the results as a 
whole, although no significant differences were appreciated, the concentration of 1 mg/mL is 
suggested to be more adequate to undergo the process under stable conditions, as the final 
nanoparticle sizes remain closer to those determined initially. 
Results concerning the zeta potential variation of CS/DS nanoparticles are shown in 
Graphic 4.4. 
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Graphic 4.4 – Zeta potential variation of different concentrations of CS/DS nanoparticles upon 
freeze-drying, as a function of the used cryoprotectant and its concentration (Zi: initial zeta 
potential; Zf: final zeta potential). Data represent mean ± SD (n = 16). 
 
Comparing sucrose with glucose, the former is suggested to have better performance 
towards the maintenance of zeta potential, with a maximum variation of 3% (1 mg/mL 
nanoparticles, 10% sucrose). In turn, zeta potential variations after freeze-drying when 5% 
glucose was used with 1 mg/mL and 2 mg/mL of nanoparticles reached 16-18%, which is 
certainly less desirable than what was observed with sucrose. However, again the standard 
deviations are high, preventing conclusions of whether glucose or sucrose has a better 
performance than the other one. Therefore, it can be said that both cryoprotectants have similar 
behaviour. 
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4.3.3. Measuring the factors’ influence on the freeze-
drying assays 
 
A well-designed experiment is very important because of the results and conclusions 
possibly drawn from it. The FD is more efficient than one factor at a time experiments and is a 
useful approach when interactions between factors may be present, in order to avoid misleading 
conclusions. 
The analysis of factors considered for CS/DS nanoparticles’ stability (Y) was based on 
the FD described in section 3.5. This approach investigates if the size and zeta potential 
variations (Y) are affected by three factors: the type of cryoprotectant (X1), the cryoprotectant 
concentrations (X2) and the nanoparticle concentrations (X3). Each factor has two levels: X1 = 
(glucose, sucrose), X2 = (5%, 10%) and X3 = (1 mg/mL, 2 mg/mL). As already mentioned in 
section 3.5, a balanced FD was planned with 16 observations per treatment, obtaining a total 
of 128 observations, represented on the contingency table (Table 4.1) shown below. 
 
Table 4.1 – Number of observations per treatment for the 23 experimental design. 
(“Cryoprotector”: glucose or sucrose; “Cryo_Conc”: cryoprotectant concentration of 5% or 
10%, w/v; “NP_Conc: nanoparticle concentration of 1 mg/mL or 2 mg/mL). 
 
 
Cryo_Conc 
5% 10% 
NP_Conc NP_Conc 
1 mg/mL 2 mg/mL 1 mg/mL 2 mg/mL 
Cryoprotector 
Glucose 16 16 16 16 
Sucrose 16 16 16 16 
 
 
4.3.3.1. Case study 1: Size variation 
 
This study examined the effect of the aforementioned factors on the variation of CS/DS 
nanoparticle size. A FD was performed and the underlying assumptions were inspected. 
Moderate departures from normality are tolerated in the case of a balanced FD, as seen by the 
examination of the Q-Q plot (Figure 4.3). As suggested by Montgomery et al, to assess this 
normality, “the central observations are more important than the ones present on the extremes” 
(112). 
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Figure 4.3 – Normal Q-Q plot for residuals for the size factorial design (FD). 
 
The test of homogeneity of variances (Levene’s test) is robust against normality 
assumption (112,125). Moreover, if the assumption of the homogeneity of variance fails, the 
test statistic is only slightly affected in the balanced design (112), as in this case (p_value = 
0.041). Inspection of the standardized and studentized residuals and Cook’s distance was 
performed to discover outliers and influential observations (see Annexes B1.1 and B1.2). These 
are problematic because they can influence the results of the analysis and because their 
presence may be a sign that the model fails to capture important characteristics of the data 
(112). 
The pareto plot from the linear adjustment is seen in Figure 4.4. 
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Figure 4.4 – Pareto plot for the size variation (* means p_value < 0.05). 
 
The pareto plot shows that the factor Cryoprotector is significant and has a positive 
increasing effect (0.059) on size variation. The next factors decrease in magnitude: NP_Conc 
(0.041), NP_Conc*Cryoprotector (0.024) and so on. From these factors, only the cryoprotector 
revealed to be statistically significant (p_value = 0.042), meaning that it is the sole responsible 
for the observed size variation (see Annex B1.3). Furthermore, an analysis between the two 
cryoprotectors is performed. Descriptive analysis for each cryoprotector is in Table 4.2. 
 
Table 4.2 – Some of the descriptive statistics for each cryoprotector. 
 
 Cryoprotector N Mean Std. Deviation 
RatioSize 
Glucose 64 1,04820 ,379182 
Sucrose 64 1,16694 ,255210 
 
Additionally, as it can be seen in Table 4.2, the mean of results obtained for glucose is 
closer to the ideal ratio of 1 comparing with sucrose. Nevertheless, the comparison between 
both cryoprotectants should be performed by means of the coefficient of variation (CV), since 
they have different means. The CV is an important statistical dispersion measure that analyses 
variation of the data round its mean, and can be calculated through the formula 
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CV (%) =  
SD
mean
× 100 
 
where “SD” is the standard deviation. For glucose, the CV is 36.2% and for sucrose is 21.9%, 
meaning that the variability for both is lower (in general, CV < 50%) and the mean can be 
considered representative for both samples. Even though sucrose presents lower CV than 
glucose, the results suggest that the latter is more adequate to undergo the process under stable 
conditions, as the final nanoparticle sizes remain closer to the ideal ratio of 1. 
 
4.3.3.2. Case study 2: Zeta potential variation 
 
The approach applied to the study of size variation was further applied on zeta potential. 
A FD was performed and the underlying assumptions were also inspected. The goodness of the 
fit can be observed in the Q-Q plot of the residuals represented in Figure 4.5, and through the 
Levene’s test (p_value = 0.899). 
 
 
Figure 4.5 – Normal Q-Q plot for residuals for the zeta potential factorial design (FD). 
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Inspection of the standardized and studentized residuals and Cook’s distance was 
performed to discover outliers and influential observations (see Annex C1.1 and C1.2). 
The pareto plot from the linear adjustment is seen in Figure 4.6. 
 
 
Figure 4.6 – Pareto plot for zeta potential variation (* means p_value < 0.05). 
 
The pareto plot shows that the factors Cryoprotector, Cryo_Conc and their combination 
Cryoprotector*Cryo_Conc are significant. The main factors have a reducing effect on the 
outcome, - 0.044 and -0.034, respectively, and the two-factor interaction has a positive 
increasing effect (0.043) on the outcome (zeta potential variation).  
From FD model, the p_values = 0.002, 0.016 and 0.003 were obtained for the factors 
Cryoptoyector, Cryo_Conc and their combination Cryoprotector*Cryo_Conc, respectively, as 
presented in the ANOVA table (Annex C1.3).  
Moreover, a 22 FD was performed and the results are shown in Annex C1.4 and C1.5. 
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4.3.4. Evaluation of the stability of freeze-dried CS/DS 
nanoparticles during storage at room temperature 
 
The previous study demonstrated the ability of glucose and sucrose to act as 
cryoprotectants of CS/DS nanoparticles. However, the reconstitution of cakes was performed 
in fresh freeze-dried samples in all cases. Nevertheless, it was deemed adequate to also verify 
the stability of these cakes along time, that is, to store freeze-dried nanoparticles for 90 days in 
a desiccator (room temperature) and perform the reconstitution each 15 days, after which 
nanoparticle size and zeta potential were characterized. The obtained results for size variation 
are displayed in Graphics 4.5 (glucose) and 4.6 (sucrose). 
 
 
Graphic 4.5 – Size variation along time (90 days) of different concentrations of CS/DS 
nanoparticles freeze-dried with glucose, upon storage of the cake at room temperature (Di: 
initial diameter; Df: final diameter). Data represent mean ± SD (n ≥ 4).  
 
Although some variations occurred along the assay, the general information deserving 
a mention is that the concentration of 5% is apparently more adequate to ensure the stability of 
nanoparticle’s size, as the measured variation remained closer to 1. Nevertheless, even at these 
conditions, a variation of 30-50% was registered in nanoparticle size, after 90 days, contrasting 
with only 3-5% at days 60 or 75. This suggests that possibly a period of 60 or 75 days is the 
maximum admissible for nanoparticle storage in these conditions. The use of 10% glucose, 
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particularly when nanoparticles are at 2 mg/mL results in strong increase of nanoparticle size 
(variation of 2.6 ± 1.9, upon 90 days).  
In turn, nanoparticles formulated with sucrose resulted in more severe variations, 
observed for the majority of tested conditions. As displayed in Graphic 4.6, and especially if 
particularly comparing the final size of nanoparticles with that registered initially, size 
variations range between 2% (1 mg/mL, 5% (w/v) sucrose) and 38% (2 mg/mL, 5% (w/v) 
sucrose). However, as a general view, having 2 mg/mL and sucrose concentration of 5% is 
possibly the best option to preserve nanoparticle size. As also observed for glucose, a maximum 
storage of 75 days is perhaps more adequate (size variation of 8%). 
 
 
Graphic 4.6 – Size variation along time (90 days) of different concentrations of CS/DS 
nanoparticles freeze-dried with sucrose, upon storage of the cake at room temperature (Di: 
initial diameter; Df: final diameter). Data represent mean ± SD (n = 5). 
 
The long-term effect on zeta potential was also characterised and results are displayed 
in Graphics 4.7 (glucose) and 4.8 (sucrose). 
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Graphic 4.7 – Zeta potential variation along time (90 days) of different concentrations of 
CS/DS nanoparticles freeze-dried with glucose upon storage as a cake at room temperature (Zi: 
initial diameter; Zf: final diameter). Data represent mean ± SD (n = 5). 
 
When glucose was used as cryoprotectant, the concentration of 10% (w/v) was the one 
showing better ability to preserve the zeta potential, independently of the used concentration 
of nanoparticles (Graphic 4.7). In these conditions, and focusing on the end of the study, the 
zeta potential variation varies between 2% and 13%. Nevertheless, when 5% glucose was used 
the variations did not go beyond 17% (after 90 days).  
In sucrose, the variations did not go beyond 25% in the whole study (Graphic 4.8). 
There is a general decrease of zeta potential registered on day 90 (25-30% comparing with 
initial values), although at day 75 several conditions provide maximal zeta potential variations 
of 7%, which is considered acceptable. 
 
0.0
0.2
0.4
0.6
0.8
1.0
1.2
1.4
1.6
1.8
2.0
0 15 30 45 60 75 90
Z
et
a 
p
o
te
n
ti
al
 v
ar
ia
ti
o
n
 (
Z
f/
Z
i)
Days
1 mg/mL 5% 1 mg/mL 10%
2 mg/mL 5% 2 mg/mL 10%
Chitosan/dextran sulfate nanoparticles: stability evaluation and 
assessment of the effect of different acidic media on nanoparticle preparation 
 
41 
 
 
Graphic 4.8 – Zeta potential variation along time (90 days) of different concentrations of 
CS/DS nanoparticles freeze-dried with sucrose upon storage of the cake at room temperature 
(Zi: initial zeta potential; Zf: final zeta potential). Data represent mean ± SD (n = 5). 
 
Considering the results as a whole, it is suggested that glucose has a better performance 
regarding the long-term preservation of the cakes and the inherent characteristics of 
nanoparticles. Nevertheless, it should be assumed that results are quite variable, inclusive when 
different storage periods are considered, which does not allow rigorous conclusions. In spite of 
that, assuming a relatively better performance of glucose, this would be in line with the 
observations resulting from the freeze-drying study presented above, where it was also 
suggested that glucose has a better contribution for the maintenance of nanoparticle 
characteristics when fresh freeze-dried samples were analysed. 
During the performance of this assay, temperature and humidity of the laboratory were 
controlled. Nanoparticle cakes were stored in a desiccator with silica, placed in a laboratory 
equipped with air-conditioning. The control of temperature and relative humidity are very 
important in stability studies and general storage of pharmaceutical formulations. EMA has a 
guideline on this matter, setting that long-term stability studies should be performed at room 
temperature (25 ± 2 ºC) and 60% relative humidity (± 5%) (126). Even though the proposed 
document is directed to large-scale trials, it can be adapted to the laboratory setting. 
During the 90 days, at least one measurement of temperature and relative humidity was 
performed using a thermo-hygrometer. The mean temperature, determined from the daily data, 
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was 23.3 ± 1.4 ºC and the mean relative humidity was 49.4 ± 9.7%. Only the temperature is, 
thus, in relative accordance with the guideline. The registered relative humidity was lower, 
probably due to the fact that the assay was conducted between August and October, a time 
when weather is dry. Additionally, as air conditioning was continuously turned on, the relative 
humidity of the laboratory decreased. 
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5. Conclusion and future lines of work 
 
From the laboratory work that was performed, it was verified that polyelectrolyte 
complexation is a valid method to produce nanoparticle based on chitosan and dextran sulfate, 
as these displayed adequate characteristics of size and zeta potential regarding a drug delivery 
approach. The production of nanoparticles was possible using different acidic media to dissolve 
chitosan (acetic acid and hydrochloric acid), although the concentration of the acid is a 
parameter requiring attention. The produced nanoparticles, which had predominant chitosan 
content, displayed sizes above 500 nm, thus requiring further optimization to enable the 
production of more adequate nanocarriers for drug delivery purposes (size below 500 nm). 
Moreover, an unexpected tendency was detected regarding zeta potential. Overall, further 
studies need to be performed to enable objective conclusions regarding the influence of acidic 
media used to dissolve chitosan, on the final characteristic of nanoparticles. 
When stored as aqueous suspension at 4 ºC, CS/DS nanoparticles only keep stable 
physicochemical characteristics for 50 days, after which important variations are detected. A 
freeze-drying study was performed to verify the ability of the technique to stabilise 
nanoparticles, testing the capacity of sucrose and glucose as cryoprotectants. Although with 
some variations in their behaviour, both carbohydrates were capable of maintaining 
nanoparticle characteristics (size and zeta potential) relatively stable. Additionally, based on 
the results of the statistical analysis, the choice of cryoprotectant is a decisive factor for the 
differences detected in CS/DS nanoparticle size variation. As for the zeta potential, not only 
the cryoprotector, but also its concentration and the combination of both factors affect 
significantly this parameter. Nevertheless, the overall analysis has led to the conclusion that 
glucose has a better behaviour on preserving nanoparticle characteristics.  
A step forward in this work would be the association of a therapeutic molecule of 
interest and the evaluation of the freeze-drying process on the drug carrier. Not only 
physicochemical characteristics would be examined, but also the effect of the freeze-drying 
process on drug encapsulation and release. 
The freeze-drying approach could be also extended to other polysaccharide-based 
nanocarriers, in order to establish a general protocol permitting the stabilisation of this kind of 
nanoparticles, which are attracting much attention in drug delivery.  
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7. Annexes 
 
ANNEX LIST 
Annex A: Flowcharts detailing the steps required for the production of nanosuspensions 
Annex A1.1 – Flowchart for the preparation of 1 mg/mL nanoparticle suspensions. 
Annex A1.2 – Flowchart for the preparation of 2 mg/mL nanoparticle suspensions. 
 
Annex B: Statistical study for the response variable “Size ratio” 
 Annex B1.1 – The standardized dispersion plot from which two outliers were detected, 
#23 (2.278) and #90 (2.091). 
Annex B1.2 – The Cook’s distance dispersion plot where two influential points can be 
detected. Since there is not any Cook’s distance bigger than 1, there are no influential 
observations among the data.  
Annex B1.3 – Analysis of variance table for size ratio. “Cryo_Conc” refers to the 
concentration of carbohydrate used on the freeze-drying process – 5% or 10%; “NP_Conc” 
refers to the concentration of nanoparticles on the sample that was submitted to freeze-drying 
– 1 or 2 mg/mL; “Cryoprotector” refers to the carbohydrate used on the process – glucose or 
sucrose. 
  
Annex C: Statistical study for the response variable “Zeta potential ratio” 
 Annex C1.1 – The standardized dispersion plot. 
Annex C1.2 – The Cook’s distance dispersion plot where the values are within the 
values considered for cut-off. 
Annex C1.1 - Analysis of variance table for size ratio. “Cryo_Conc” refers to the 
concentration of carbohydrate used on the freeze-drying process – 5% or 10%; “NP_Conc” 
refers to the concentration of nanoparticles on the sample that was submitted to freeze-drying 
– 1 or 2 mg/mL; “Cryoprotector” refers to the carbohydrate used on the process – glucose or 
sucrose. 
Annex C1.4 – The number of observations per treatment for the 22 factorial design. 
Annex C1.5 – Analysis of variance table for size ratio. “Cryo_Conc” refers to the 
concentration of carbohydrate used on the freeze-drying process – 5% or 10%; “Cryoprotector” 
refers to the carbohydrate used on the process – glucose or sucrose.  
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Annex A: Flowcharts detailing the steps required for the production of nanosuspensions 
 
Annex A1.1 – Flowchart for the preparation of 1 mg/mL nanoparticle suspensions. 
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Annex A1.2 – Flowchart for the preparation of 2 mg/mL nanoparticle suspensions. 
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Annex B: Statistical study for the response variable “Size ratio” 
 
Annex B1.1 – The standardized dispersion plot from which two outliers were detected, #23 
(2.278) and #90 (2.091). 
 
 
Annex B1.2 – The Cook’s distance dispersion plot where two influential points can be 
detected. Since there is not any Cook’s distance bigger than 1, there are no influential 
observations among the data. 
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Annex B1.3 – Analysis of variance table for size ratio. “Cryo_Conc” refers to the concentration 
of carbohydrate used on the freeze-drying process – 5% or 10%; “NP_Conc” refers to the 
concentration of nanoparticles on the sample that was submitted to freeze-drying – 1 or 2 
mg/mL; “Cryoprotector” refers to the carbohydrate used on the process – glucose or sucrose. 
Source 
Type III Sum 
of Squares 
df 
Mean 
Square 
F Sig. 
Cryo_Conc ,008 1 ,008 ,073 ,788 
NP_Conc ,213 1 ,213 1,990 ,161 
Cryoprotetor ,451 1 ,451 4,220 ,042* 
Cryo_Conc * 
NP_Conc 
,037 1 ,037 ,349 ,556 
Cryo_Conc * 
Cryoprotetor 
,000 1 ,000 ,001 ,975 
NP_Conc * 
Cryoprotetor 
,072 1 ,072 ,676 ,413 
Cryo_Conc * 
NP_Conc * 
Cryoprotetor 
,001 1 ,001 ,008 ,928 
Error 12,830 120 ,107   
*statistically significant at 5% 
  
Chitosan/dextran sulfate nanoparticles: stability evaluation and 
assessment of the effect of different acidic media on nanoparticle preparation 
 
58 
 
Annex C: Statistical study for the response variable “Zeta potential ratio” 
 
Annex C1.1 – The standardized dispersion plot. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Annex C1.2 – The Cook’s distance dispersion plot where the values are within the values 
considered for cut-off. 
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Annex C1.3 - Analysis of variance table for size ratio. “Cryo_Conc” refers to the concentration 
of carbohydrate used on the freeze-drying process – 5% or 10%; “NP_Conc” refers to the 
concentration of nanoparticles on the sample that was submitted to freeze-drying – 1 or 2 
mg/mL; “Cryoprotector” refers to the carbohydrate used on the process – glucose or sucrose. 
Source 
Type III Sum 
of Squares 
df 
Mean 
Square 
F Sig. 
Cryo_Conc .149 1 .149 5.920 .016* 
Cryoprotetor .242 1 .242 9.603 .002* 
NP_Conc .044 1 .044 1.754 .188 
Cryo_Conc * 
Cryoprotetor 
.238 1 .238 9.429 .003* 
Cryo_Conc * 
NP_Conc 
.022 1 .022 .857 .357 
Cryoprotetor * 
NP_Conc 
.001 1 .001 .053 .819 
Cryo_Conc * 
Cryoprotetor * 
NP_Conc 
.028 1 .028 1.120 .292 
Error 3.030 120 .025   
*statistically significant at 5% 
 
 
Annex C1.4 – The number of observations per treatment for the 22 factorial design. 
 
Cryo_Conc 
5% 10% 
Cryoprotector 
Glucose 32 32 
Sucrose 32 32 
 
 
Annex C1.5 – Analysis of variance table for size ratio. “Cryo_Conc” refers to the concentration 
of carbohydrate used on the freeze-drying process – 5% or 10%; “Cryoprotector” refers to the 
carbohydrate used on the process – glucose or sucrose. 
Source 
Type III Sum 
of Squares 
df 
Mean 
Square 
F Sig. 
Cryo_Conc .149 1 .149 5.930 .016 
Cryoprotetor .242 1 .242 9.620 .002 
Cryo_Conc * 
Cryoprotetor 
.238 1 .238 9.445 .003 
Error 3.125 124 .025   
 
